GCGR and metabolic dysfunction-associated steatotic liver disease: This review provides (1) insights into the pathogenesis of NAFLD including the potential involvement of GLP-1 and glucagon, (2) a critical appraisal of the applicability of GLP-1RAs in NAFLD treatment, and (3) a review of the evidence for GLP-1/glucagon receptor co-agonism as a novel approach in the treatment of NAFLD.